Mark Walters, Md

This early-stage trial tests a one-time infusion of the patient's own blood stem cells, which have been corrected using CRISPR gene editing to fix the sickle cell mutation. The goal is to reduce painful blockages in blood vessels (vaso-occlusive events) and improve quality of lif…